Baseline clinical and genetic features of CLL/SLL in 67 venetoclax-treated patients, subgrouped by outcome
| . | All patients . | Nonprogressors . | RT (Hodgkin) . | RT (DLBCL) . | CLL progression . |
|---|---|---|---|---|---|
| Number (N) | 67 | 42 | 3 | 14 | 8 |
| Age, y, median (range) | 68 (20-87) | 68 (20-87) | 62 (54-73) | 62 (47-74) | 70 (65-78) |
| Prior therapies, median (range) | 3 (1-12) | 3 (1-12) | 2 (1-3) | 4 (2-8) | 4 (1-7) |
| F-refractory, n (n/N%) | 33 (49) | 16 (38) | 2 (67) | 8 (57) | 7 (88) |
| Bulky disease, n (n/N%) | 32 (48) | 16 (38) | 1 (33) | 10 (71) | 5 (63) |
| Venetoclax <400 mg/d, n (n/N%) | 18 (27) | 6 (14) | 1 (33) | 8 (57) | 3 (38) |
| Concurrent rituximab, n (n/N%) | 16 (24) | 12 (29) | 2 (67) | 1 (7) | 1 (13) |
| Del11q, n (n/N%) | 17 (25) | 12 (29) | 0 (0) | 3 (21) | 2 (25) |
| Del17p, n (n/N%) | 27 (40) | 17 (40) | 0 (0) | 8 (57) | 2 (25) |
| Del17p and/or TP53 mutation, n/N (%) | 34/58 (59) | 20/35 (57) | 0/1 (0) | 10/14 (71) | 4/8 (50) |
| Complex karyotype, n/N (%) | 16/38 (42) | 6/23 (26) | 1/1 (100) | 5/8 (63) | 4/6 (67) |
| IGHV unmutated, n/N (%) | 28/35 (80) | 14/18 (78) | 2/2 (100) | 8/10 (100) | 4/5 (100) |
| . | All patients . | Nonprogressors . | RT (Hodgkin) . | RT (DLBCL) . | CLL progression . |
|---|---|---|---|---|---|
| Number (N) | 67 | 42 | 3 | 14 | 8 |
| Age, y, median (range) | 68 (20-87) | 68 (20-87) | 62 (54-73) | 62 (47-74) | 70 (65-78) |
| Prior therapies, median (range) | 3 (1-12) | 3 (1-12) | 2 (1-3) | 4 (2-8) | 4 (1-7) |
| F-refractory, n (n/N%) | 33 (49) | 16 (38) | 2 (67) | 8 (57) | 7 (88) |
| Bulky disease, n (n/N%) | 32 (48) | 16 (38) | 1 (33) | 10 (71) | 5 (63) |
| Venetoclax <400 mg/d, n (n/N%) | 18 (27) | 6 (14) | 1 (33) | 8 (57) | 3 (38) |
| Concurrent rituximab, n (n/N%) | 16 (24) | 12 (29) | 2 (67) | 1 (7) | 1 (13) |
| Del11q, n (n/N%) | 17 (25) | 12 (29) | 0 (0) | 3 (21) | 2 (25) |
| Del17p, n (n/N%) | 27 (40) | 17 (40) | 0 (0) | 8 (57) | 2 (25) |
| Del17p and/or TP53 mutation, n/N (%) | 34/58 (59) | 20/35 (57) | 0/1 (0) | 10/14 (71) | 4/8 (50) |
| Complex karyotype, n/N (%) | 16/38 (42) | 6/23 (26) | 1/1 (100) | 5/8 (63) | 4/6 (67) |
| IGHV unmutated, n/N (%) | 28/35 (80) | 14/18 (78) | 2/2 (100) | 8/10 (100) | 4/5 (100) |
The nonprogressor subgroup (n = 42) includes 6 patients who came off study for reasons other than disease progression (see main text for details). N, number per group (denominator); n, number of patients with a specific variable (numerator). Where not all patients were tested for a specific variable (last 3 rows), the denominator has been adjusted for that analysis, so that N = number of patients tested for that variable.